Finance

Beta
Ask
Lists
AVTX:NASDAQ
Avalo Therapeutics Inc
$17.32
+1.38%
(+0.24) 1D
Jun 23, 9:38:06 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVTX...
Open
$16.78
High
$17.54
Low
$16.71
Mkt. cap
904.13M
Avg. vol.
1.70M
Volume
11.34K
52-wk high
$24.27
52-wk low
$4.50
EPS
-$5.83
Beta
0.83
Shares outstanding
52.57M
No. of employees
33
Open
$16.78
High
$17.54
Low
$16.71
Mkt. cap
904.13M
Avg. vol.
1.70M
Volume
11.34K
52-wk high
$24.27
52-wk low
$4.50
EPS
-$5.83
Beta
0.83
Shares outstanding
52.57M
No. of employees
33
News stories
From sources across the web
About Avalo Therapeutics Inc
CEO-
Employees33
Founded2011
HeadquartersRockville, Pennsylvania, United States
SectorBiotechnology
Websiteavalotx.com
Analyst Ratings
Based on 11 analysts giving stock ratings to AVTX in the past 3 months
Strong Buy
Buy
11
Hold
0
Sell
0
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for AVTX in the last 3 months.
Highest
Current $17.32
$60.00 (+246.52%)
Average
$45.90 (+165.09%)
Lowest
$34.00 (+96.36%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Initiated
$35.00
+102.1%
06/12/2026
Stacy Ku
TD Cowen
Buy
Maintained
-
-
06/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$39.00
+125.2%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$34.00
+96.4%
05/14/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$45.00
+159.9%
05/14/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$35.00
+102.1%
05/14/2026
Julian Harrison
BTIG
Buy
Maintained
$58.00
+235%
05/13/2026
Jason Butler
Citizens JMP
Buy
Maintained
$55.00
+217.6%
05/14/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
$60.00
+246.5%
05/11/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$50.00
+188.8%
05/06/2026
Andy Chen
Wolfe Research
Buy
Initiated
$48.00
+177.2%
04/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
59.00K
-
Cost of goods sold
10.66M
9.99M
8.78M
10.15M
Cost of revenue
10.66M
9.99M
8.78M
10.15M
Research and development expenses
3.41M
3.63M
4.48M
3.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.24M
5.58M
6.53M
6.85M
Operating expense
8.66M
9.21M
11.02M
10.75M
Total operating expenses
19.32M
19.20M
19.80M
20.90M
Operating income
-19.32M
-19.20M
-19.74M
-20.90M
Other non operating income
-2.54M
-12.53M
5.17M
480.00K
EBT including unusual items
-20.75M
-30.61M
-13.59M
-19.62M
EBT excluding unusual items
-20.75M
-30.61M
-13.59M
-19.62M
Income tax expense
16.00K
11.00K
130.00K
12.00K
Effective tax rate
-0.08%
-0.04%
-0.96%
-0.06%
Other operating expenses
-
-
-
-
Net income
-20.76M
-30.62M
-13.72M
-19.63M
Net profit margin
-
-
-23,254.24%
-
Earnings per share
-1.92
-2.19
-0.37
-0.98
Interest and investment income
1.10M
1.12M
984.00K
803.00K
Interest expense
-
-
-
-
Net interest expenses
1.10M
1.12M
984.00K
803.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.18M
-19.14M
-19.73M
-20.88M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer